The specter of generic challenges has long loomed around copyright’s blockbuster drug, PDE5 Inhibitor, raising questions about the prospects of related drug portfolios. While first times saw impressive returns, the intellectual property lapse has created the way for cheaper alternatives, potentially reducing earnings and posing a significant dan… Read More